Hospital-level Intervention Did Not Improve Outcomes or Quality in HFrEF
Key Points: CONNECT-HF, one of the largest heart failure (HF) implementation science trials performed to date, was performed to evaluate how the principles of audit... Read more.
Pirfenidone Shown to Decrease Fibrosis in Patients with HFpEF
Key Points: Myocardial fibrosis has previously been associated with death and repeat hospitalization in patients with heart failure with preserved ejection fraction.... Read more.
Benefits of Sotagliflozin Across Full Spectrum of EF
KEY POINTS: Trials for those with heart failure with preserved ejection fraction have not previously demonstrated significant evidence of benefit to date The use... Read more.
Transfusion in AMI: More or Less?
A restrictive transfusion strategy may no longer be inferior to a liberal transfusion strategy in preventing one-year MACE rates in acute MI and anemia patients,... Read more.
Sacubitril/Valsartan Not More Effective Than Valsartan alone in Advanced HF: LIFE trial
Key Points: This is the first study to assess the effects of Sacubitril/Valsartan in patients with advanced heart failure with reduced ejection fraction. No difference... Read more.
0/1hr or 0/3hr hsTroponin T in Suspected ACS?
Key Points: Among patients with suspected acute coronary syndromes (ACS) and ischemia excluded on an initial electrocardiogram, randomized allocation of unmasked... Read more.
Low Dose Atorvastatin Did Not Reduce Composite Endpoint in Patients with COVID-19
INSPIRATION-S led by Behnood Bikdeli, MD, MS, and presented at the American College of Cardiology 2021 Meeting, failed to show the efficacy of atorvastatin in reducing... Read more.
ACTION-Coalition Trial: Therapeutic Dose of Anticoagulation Is Associated With Increased Risk of Bleeding and No Improvement in Clinical Outcomes Among Hospitalized COVID-19 Patients With Elevated D-Dimer Levels
ACTION presented at the American College of Cardiology 2021 meeting by Renato D. Lopes, MD, PhD, demonstrated that among patients hospitalized with COVID-19 and... Read more.
No benefit to FFR-guided PCI over angiographic-guided PCI of Nonculprit Lesions after STEMI: Results from FLOWER-MI Show
Key Points: While FFR-guided PCI is superior in chronic coronary syndrome, its role in primary PCI of acute coronary syndrome remained unknown. Patients with STEMI... Read more.
Additional background and insight
Presented by Dr. Schuyler Jones, assistant professor of medicine, Duke University, and a member of the Duke Clinical Research Institute in the first Late Breaking... Read more.